tbuckley/cabot-search huggingface dataset:
OC-023 Can we predict length of stay in patients admitted with acute upper gastrointestinal bleeding?
Authors: V Jairath, R Logan, S Hearnshaw, S Travis, M Murphy, K Palmer
Journal: Gut (2010)

<h3>Introduction</h3> Acute upper gastrointestinal bleeding (AUGIB) is a common cause of admission to hospital in the UK with an annual incidence of 50–150 per 100 000 cases and a stubbornly high mortality of around 10–14%. Thus AUGIB represents a huge economic burden to the NHS. Enabling clinicians and bed managers to predict the likely length of stay of those patients admitted could aid triage to an appropriate hospital area and facilitate the multidisciplinary team in discharge planning. We analysed if length of hospital stay can be predicted from the clinical and/or full Rockall score. <h3>Methods</h3> Further analyses were performed on patients included in the 2007 UK Comparative Audit of Upper Gastrointestinal Bleeding and the Use of Blood.1 In this study prospective data were collected electronically on consecutive patients presenting to all UK hospitals with AUGIB between 1 May and 30 June 2007. <h3>Results</h3> Data were available on 6750 patients across 208 UK hospitals. We restricted this analysis to new admissions with AUGIB (5550/6750). A clinical Rockall score was available for 5550 patients and a full (post endoscopy) Rockall score for 4095 patients. We analysed the median length of stay by clinical and full Rockall score for all new patients admitted with AUGIB. The median length of stay for a clinical Rockall score of 0–1 was 3 days. The median length of stay for a full Rockall score of zero was 2 days- each one point increase in the full Rockall score corresponded to one extra day in hospital. Non-parametric, two-tailed Spearman coefficient calculation demonstrated the correlation between Rockall score and length of stay was highly significant for both the clinical score (r=0.291, p&lt;0.01) and full score (r=0.313, p&lt;0.01). <h3>Conclusion</h3> The Rockall score was originally developed as a tool to predict mortality from AUGIB. In this retrospective analysis, we have shown that both the clinical and full Rockall score can be used to predict length of hospital stay for patients presenting with AUGIB. We have also demonstrated a median length of hospital stay of 3 days for patients with a clinical Rockall score of 0–1 which could be deemed excessive given recent further evidence supporting discharge followed by early outpatient endoscopy for such low risk patients.2
Improvised Equipment in the Home Care of the Sick.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine
Authors: I.S. Batth, A. Mitra, S. Manier, I.M. Ghobrial, D. Menter, S. Kopetz, S. Li
Journal: Annals of Oncology (2019)

Ann Oncol 2017; 28(3): 468–477 (doi: 10.1093/annonc/mdw619) The following funding information has been added: “This work was supported in part by The University of Texas MD Anderson Cancer Center Support Grant P30 CA016672.” Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicineAnnals of OncologyVol. 28Issue 3PreviewCurrent trajectory of clinical care is heading in the direction of personalized medicine. In an ideal scenario, clinicians can obtain extensive diagnostic and prognostic information via minimally-invasive assays. Information available in the peripheral blood has the potential to bring us closer to this goal. In this review we highlight the contributions of circulating tumor cells and circulating tumor DNA and RNA (ctDNA/ctRNA) towards cancer therapeutic field. We discuss clinical relevance, summarize available and upcoming technologies, and hypothesize how future care could be impacted by a combined study. Full-Text PDF Open Archive
Queries and Minor Notes.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hospital Organization and Operation.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prejudice
Authors: Vivian G. Cheung
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Society Transactions
Authors: Mark Bernhardt
Journal: JAMA Dermatology (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Pulse Versus Daily Oral Cyclophosphamide in ANCA-Associated Vasculitis
Authors: Stuart M. Levine
Journal: Annals of Internal Medicine (2010)

Letters5 January 2010Pulse Versus Daily Oral Cyclophosphamide in ANCA-Associated VasculitisStuart M. Levine, MDStuart M. Levine, MDFrom Johns Hopkins University, Baltimore, MD 21218.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-152-1-201001050-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The study by de Groot and colleagues (1) shows that the higher cumulative dosing of traditional (2 mg/kg) daily oral cyclophosphamide regimens offers no advantage over lower-dose regimens delivered by intravenous pulse for the induction of remission in patients with ANCA-associated vasculitis. However, the authors did not evaluate whether lower-dose (1.0 to 1.25 mg/kg) daily oral regimens, with their lower risks for bone marrow and bladder toxicities, would be similarly efficacious in achieving remission. Before intravenous pulse cyclophosphamide for induction of remission in this patient population is broadly recommended, comparison studies with less toxic oral regimens are ...Reference1. de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al; EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670-80. [PMID: 19451574] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Johns Hopkins University, Baltimore, MD 21218.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody—Associated Vasculitis Kirsten de Groot , Lorraine Harper , David R.W. Jayne , Luis Felipe Flores Suarez , Gina Gregorini , Wolfgang L. Gross , Rashid Luqmani , Charles D. Pusey , Niels Rasmussen , Renato A. Sinico , Vladimir Tesar , Philippe Vanhille , Kerstin Westman , Caroline O.S. Savage , and Pulse Versus Daily Oral Cyclophosphamide in ANCA-Associated Vasculitis Lorraine Harper , Kirsten de Groot , and Caroline O. Savage Pulse Versus Daily Oral Cyclophosphamide in ANCA-Associated Vasculitis Prasanta Padhan Pulse Versus Daily Oral Cyclophosphamide in ANCA-Associated Vasculitis Lee A. Hebert and Brad H. Rovin Metrics Cited ByPauci-Immune Necrotizing Glomerulonephritis 5 January 2010Volume 152, Issue 1Page: 65KeywordsBladderBone marrowConflicts of interestCyclophosphamideHeart rateToxicityVasculitis ePublished: 5 January 2010 Issue Published: 5 January 2010 CopyrightCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Seasoned AIDS Warriors Extend Arms to Rookies in the Battle Against HIV Disease
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Toxicity of Combustion Products from Burning Polymers: Development and Evaluation of Methods
Authors: P. L. Wright, C. H. Adams
Journal: Environmental Health Perspectives (1976)

Laboratory and room-scale experiments were conducted with natural and synthetic polymers: cotton, paper, wood, wool, acetate, acrylic, nylon, and urethane. Smoke and off-gases from single materials were generated in a dual-compartment 110-liter exposure chamber. Multicomponent, composite fuel loads were burned within a 100 m3 facility subdivided into rooms. In chamber experiments, mortality depended on the amount of material burned, i.e., fuel consumption (FC). Conventional dose (FC)/mortality curves were obtained, and the amount of fuel required to produce 50% mortality (FC50) was calculated. With simple flame ignition, cotton was the only material that produced smoke concentrations lethal to rats; FC50 values for cotton ranged from 2 g to 9 g, depending on the configuration of the cotton sample burned. When supplemental conductive heat was added to flame ignition, the following FC50 values were obtained; nylon, 7 g; acrylic, 8 g; newsprint, 9 g; cotton, 10 g; and wood, 11 g. Mortality resulting from any given material depended upon the specific conditions employed for its thermal decomposition. Toxicity of off-gasses from pyrolysis of phosphorus-containing trimethylol propane—polyurethane foams was markedly decreased by addition of a flame ignition source. Further studies are needed to determine the possible relevance of single-material laboratory scale smoke toxicity experiments. Room-scale burns were conducted to assess the relative contributions of single materials to toxicity of smoke produced by a multicomponent self-perpetuating fire. Preliminary results suggest that this approach permits a realistic evaluation of the contribution of single materials to the toxicity of smoke from residential fires.
FRI0056 Increased expression of the collagen internalization receptor ENDO180 in fibroblast-like synoviocytes of patients with rheumatoid arthritis
Authors: L Yan, Y Wen
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Hyperproliferative and invasion are the characteristics of fibroblast-like synoviocytes in rheumatoid arthritis (RA-FLSs), which contribute mainly to RA disease progression and ultimately to joint destruction. Endo180 is a recycling endocytic receptor that has functions to regulate cell migration and bind and internalize collagens. However, the expression of Endo180 in RA-FLSs and its underlying mechanisms remain unclear. <h3>Objectives</h3> To examine the expression of Endo180 in RA-FLSs and the role it played in RA. <h3>Methods</h3> Tissues were collected from RA patients with joint replacement surgery or arthroscopy and RA-FLSs were obtained by tissue culture; Westren blot was used to measure the expression of Endo180 in RA-FLSs. Chemically synthesized small interference RNA (siRNA) specifically targeting Endo180 gene was transfected into RA-FLSs by cationic liposome; The interference efficiency of Endo180-siRNA on the production of Endo180 mRNA and protein was determined by RT-qPCR and Western blot respectly; The proliferative inhibition rate was examined by CCK8 assay and the migration of RA-FLSs were examined by Transwell assay. <h3>Results</h3> Expression of Endo180 was obviously higher in fibroblast-like synoviocytes in RA than OA and the traumatic patients. And its expression level has positive correlation with disease activity. The proliferative inhibition rate was obviously higher in the Endo180-siRNA group than the control groups (P&lt;0.05) after transfection for 48h (8.31%±1.17%), 72h (15.93%±2.12)%), 96h (18.01%±2.78%). Transwell migration assay demonstrated the RA-FLSs through the transwell membrane in Endo180-siRNA group (21.27±6.35) were lesser than the NC-siRNA group (80.20±11.12) (P&lt;0.05)and the blank control group (82.17±10.36) (P&lt;0.05). <h3>Conclusions</h3> Endo180 may play a role in the regulation of proliferation and migration of RA-FLSs, which may provide beneficial therapeutic effects in RA. <h3>References</h3> Melander MC, Jürgensen HJ, Madsen DH,et al. The collagen receptor uPARAP/Endo180 in tissue degradation and cancer (Review).Int J Oncol. 2015 Oct;47(4):1177–88. doi: 10.3892/ijo.2015.3120. Epub 2015 Aug 12. Madsen DH, Jurgensen HJ, Ingvarsen S, et al. Endocytic collagen degradation: a novel mechanism involved in protection against liver fibrosis. J Pathol. 2012 May;227(1):94–105. doi: 10.1002/path.3981. Epub 2012 Feb 17. <h3>Disclosure of Interest</h3> None declared
WHAT'S IN A NAME?
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Characteristics and Outcomes Of Patients (pts) With Multiple Myeloma (MM) Who Develop Therapy (t)-Related Myelodysplastic Syndrome (MDS), t-Chronic Myelomonocytic Leukemia (CMML), Or t-Acute Myeloid Leukemia (AML)
Authors: Naveen Pemmaraju, Dhaval Shah, Hagop M Kantarjian, Verena Wagner, Robert Z. Orlowski, Guillermo Garcia-Manero, Farhad Ravandi, Sherry Pierce, Koichi Takahashi, Naval G. Daver, Aziz Nazha, Srdan Verstovsek, Elias J. Jabbour, Marcos J de Lima, Richard E Champlin, Jorge E. Cortes, Muzaffar H. Qazilbash
Journal: Blood (2013)
Transdermal fentanyl for postoperative pain management. A double-blind placebo study
Authors: R. A. Caplan
Journal: JAMA (1989)

A double-blind, placebo-controlled, randomized design was used to evaluate the safety and efficacy of transdermal fentanyl citrate for postoperative pain management in 42 healthy adult patients undergoing major shoulder surgery. Transdermal systems rated to deliver fentanyl citrate at a rate of 75 μg/h were applied to the skin immediately prior to surgery and worn for 24 hours. Patients in the active group required significantly less morphine than the placebo group during the 24-hour period that systems were in place (0.8 ±0.61 vs 1.3 ±0.64 mg/h) and for the first 12 hours after removal (0.3 ± 0.36 vs 0.5 ± 0.32 mg/h). The incidence of vomiting was more frequent in the active group than in the placebo group (73% vs 30%), and respiratory rate in the active group was lower than in the placebo group during the 13- to 24-hour interval of system application (14±3 vs 16±2 breaths per minute). Nevertheless, transdermal fentanyl appears to be safe and effective after orthopedic surgery in healthy adult patients. (<i>JAMA</i>1989;260:1036-1039)
SURG-05. THE IMPACT OF SURGERY IN MOLECULARLY DEFINED LOW-GRADE GLIOMA: AN INTEGRATED CLINICAL, RADIOLOGICAL AND MOLECULAR ANALYSIS
Authors: Maarten Wijnenga, Pim French, Hendrikus Dubbink, Winand Dinjens, Peggy Atmodimedjo, Johan Kros, Marion Smits, Renske Gahrmann, Geert-Jan Rutten, Jeroen Verheul, Ruth Fleischeuer, Clemens Dirven, Arnaud Vincent, Martin van den Bent
Journal: Neuro-Oncology (2017)

The WHO classification of gliomas has been revised completely and is now predominantly based on molecular criteria. This requires re-evaluation of the impact of surgery in molecularly defined low-grade glioma subtypes. We performed a retrospective study to assess the interaction between molecular markers and postoperative tumor volume on overall survival in patients with low-grade glioma. We included 228 adult patients who underwent surgery for a supratentorial low-grade glioma since 2003. Pre-and postoperative tumor volume were assessed with semi-automatic software on T2-weighted images. Targeted next-generation-sequencing was used to classify the samples according to current WHO 2016 classification. The impact of postoperative tumor volume on overall survival, corrected for molecular profile, was assessed using a Cox proportional-hazards model. Median follow-up was 5.8 years. In 39 (17.1%) of cases, glioma subtype was revised after molecular analysis. Complete resection was achieved in 35 patients (15.4%). In 54 patients (23.7%) a small tumor residue (0.1-5.0 cm3) remained. In multivariate analyses, postoperative tumor volume was associated with overall survival with a HR of 1.01 (95% CI 1.002-1.02; p=0.016) per 1 cm3 increase in volume. The impact of postoperative volume was particularly strong in IDH mutated astrocytoma patients, where even very small postoperative tumor volumes (0.1-5.0 cm3) already negatively affected overall survival (Log-rank test, p = 0.027). Our data provides the necessary re-evaluation of the impact of surgery for all molecular low-grade glioma subtypes. Importantly, even a small postoperative volume has a negative impact on overall survival in IDH mutated astrocytoma, which argues for a second-look operation in this glioma subtype even when minor residual tumor remains.